phosphoinositide 3-kinase delta

临床试验

计划入组 5 人 · 首次发布于 2017 年 6 月 6 日

招募中

NCT06249997

An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS

计划入组 3 人 · 首次发布于 2024 年 2 月 8 日

进行中（未招募）

NCT05438407

Pediatric Patients Aged 4 to 11 Years With APDS

计划入组 15 人 · 首次发布于 2022 年 6 月 30 日

药物

查看全部 5230 →

Small Molecule

Approved

Leniolisib(Joenja)

相关疾病：Activated PI3 kinase delta syndrome

C₂₁H₂₅F₃N₆O₂

KIT-2014

X-339

机构

查看全部 1394 →

Algemeen Ziekenhuis Delta

Belgium

Delta Crystallon BV

United States of America

Delta Ecommerce LLC

United States

资讯

查看全部 13252 →

去年

Pharming Group Initiates Phase II Trial of Leniolisib for Primary Immunodeficiencies

去年

MHRA Approves Joenja (leniolisib) as First Treatment for Rare Immune Disease APDS

去年

临床试验

TGR1202 in Relapsed and Refractory Follicular Lymphoma

An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS

Pediatric Patients Aged 4 to 11 Years With APDS

药物

Leniolisib(Joenja)

KIT-2014

X-339

机构

Algemeen Ziekenhuis Delta

Delta Crystallon BV

Delta Ecommerce LLC

资讯

Pharming Group Initiates Phase II Trial of Leniolisib for Primary Immunodeficiencies

MHRA Approves Joenja (leniolisib) as First Treatment for Rare Immune Disease APDS

Pharming's Leniolisib Shows Positive Phase 3 Data in Young Children with APDS